Online Only Articles

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Hemato-Oncology Department, IDIBAPS, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain
Hematology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain
CIBERONC, Barcelona, Spain;Hematology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain;Hematopathology Unit, Pathology Department, Hospital Clinic-IDIBAPS, Barcelona, Spain
CIBERONC, Barcelona, Spain;Hematology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain;Hematopathology Unit, Pathology Department, Hospital Clinic-IDIBAPS, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain;Vall d’Hebron University Hospital (HUVH) and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain;Hematopathology Unit, Pathology Department, Hospital Clinic-IDIBAPS, Barcelona, Spain
Hemato-Oncology Department, IDIBAPS, Barcelona, Spain;CIBERONC, Barcelona, Spain
Vol. 102 No. 11 (2017): November, 2017 https://doi.org/10.3324/haematol.2017.168930